|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: A pilot study显示文摘AIM: Various side effects have been reported in patients infected with hepatitis C virus (HCV) who were treated with interferon-alpha (IFN-α), including the appearance or exacerbation of underlying autoimmune diseases and the development of a variety of organ and non-organ specific autoantibodies (NOSA). However, very few studies in adults have been strictly designed to address: whether the prevalence and the titre of organ and NOSA in serial samples of HCV-treated patients were affected by IFN-α, and the impact of these autoantibodies on the treatment outcome of HCV patients.METHODS: We investigated whether parietal cell autoantibodies (PCA) and/or NOSA were related with treatment-outcome in 57 HCV-treated patients (19 sustainedresponders, 16 relapsers, 22 non-responders). Serum samples from patients were studied blindly at three timepoints (entry, end of treatment and end of followup). For the detection of autoantibodies we used indirect immunofluorescence, commercial and in-house ELISAs.RESULTS: Sustained biochemical response was associated with ANA-negativity at the entry or end of follow up. Sustained virological response was associated with the absence of PCA at the entry. Combined virological and biochemical sustained response (CVBSR) was associated with the absence of antinuclear antibodies (ANA) at the end of follow up and PCA-negativity at the entry. Sustained virological and CVBSR were associated with a reduction of ANA and SMA titers during therapy.CONCLUSION: Although PCA and/or NOSA seropositivity should not affect the decision to treat HCV patients, the presence of some of them such as ANA, PCA and SMA before treatment or their increase during therapy with IFN- α may predict a worse response, indicating the need for a closer monitoring during treatment of HCV patients positive for these autoantibodies. | Nikolaos K.Gatselis Sarah P.Georgiadou Nikolaos Tassopoulos Kalliopi Zachou Christos Liaskos Angelos Hatzakis Georgios N.Dalekos | 2005 | World Journal of Gastroenterology2005，11，4： | 10 |
| 2 | Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years显示文摘 | Stephanos J. Hadziyannis Nicolaos C. Tassopoulos E. Jenny Heathcote Ting–Tsung Chang George Kitis Mario Rizzetto Patrick Marcellin Seng Gee Lim Zachary Goodman Jia Ma Carol L. Brosgart Katyna Borroto–Esoda Sarah Arterburn Steven L. Chuck | 2006 | Gastroenterology2006，，6： | 3 |
| 3 | Efficacy of lamivudine in patients with hepatitis B e antigen-negative hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B显示文摘 | Tassopoulos NC Volpes R Pastore G | | 0，，： | 3 |
| 4 | Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years显示文摘 | Hadziyannis SJ Tassopoulos NC Heathcote EJ | | 0，，： | 3 |
| 5 | Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years显示文摘 | Stephanos J. Hadziyannis Nicolaos C. Tassopoulos E. Jenny Heathcote Ting–Tsung Chang George Kitis Mario Rizzetto Patrick Marcellin Seng Gee Lim Zachary Goodman Jia Ma Carol L. Brosgart Katyna Borroto–Esoda Sarah Arterburn Steven L. Chuck | 2006 | Gastroenterology2006，，6： | 2 |
| 6 | Longterm therapy with adefovir dipivoxil for HBeAG-negative chronic hepatitis B for up to 5 years显示文摘 | Hadziyannis SJ Tassopoulos NC Heathcote EJ | 2006 | Gastroenterology2006，131，6： | 1 |
| 7 | Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B显示文摘 | Hadziyannis SJ Tassopoulos NC Heathcote EJ | 2005 | N Engl J Med2005，352，26： | 1 |
| 8 | Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B显示文摘 | Hadziyannis SJ Tassopoulos NC Heathcote E J | 2003 | N Engl J Med2003，348，9： | 1 |
| 9 | Long - term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HbeAg negative chronic hepatitis B: results after 5 years of therapy显示文摘 | Hadziyannis S Tassopoulos N Chang TT | 2005 | Hepatology2005，42，1： | 1 |
| 10 | Three-year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B patients in a long-term safety and efficacy study显示文摘 | HADZIYANNIS S TASSOPOULOS N CHANG TT | 2004 | J Hepatol2004，42，1： | 1 |
| 11 | Long-term therapy with adefovir dipivoxil for HBeAg-nega- rive chronic hepatitis B for up to 5 years 显示文摘 | Hadziyannis S J Tassopoulos N C Heathcote E J | 2006 | Gastroenterol- ogy2006，131，6： | 1 |
| 12 | Efficacy of lamivudine in patients with hepatitis B e antigen- negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B: Lamivudine Precore Mutant Study Group显示文摘 | Tassopoulos NC Volpes R Pastore G | 1999 | Hepatology1999，29，3： | 1 |
| 13 | Long- term therapy with adefovir dipivoxil for FIBeAg-negative chronic hepatitis B显示文摘 | Hadziyannis S J Tassopoulos NC Heathcote EJ | 2005 | N Engl J Med2005，352，26： | 1 |
| 14 | Long-term therapy with adefovir dipivoxil for HBeAg-nega- tive chronic hepatitis B 显示文摘 | Hadziyannis S J Tassopoulos N C Heathcote E J | 2005 | N Engl J Med2005，352，26： | 1 |
| 15 | dipivoxil for HBeAgup to 5 years 显示文摘 | Hadziyannis SJ Tassopoulos NC Long-term therapy with adefovir negative chronic hepatitis B for Gastroenterology 2006 131 (6) : Heathcote EJ | 2006 | 1743-17512006，，： | 1 |
| 16 | Adefovir dipivoxil for the treatment of hepatitis B e antigen- negative chronic hepatitis B显示文摘 | Hadziyannis S J Tassopoulos N C Heathcote E J | 2003 | N Engl J Med2003，348，9： | 1 |
| 17 | Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis显示文摘 | Rizzetto M Tassopoulos NC Goldin RD | 2005 | Br J Hepa- tol2005，42，： | 1 |
| 18 | An epidemic of hepatitis A in an institution for young children 显示文摘 | Tassopoulos N C Roumeliotou-Karayannis A Sakka M | 1987 | Am J Epidemiol1987，125，2： | 1 |
| 19 | Efficacy of lamivudine in patients with hepatitis B antigen-negative/hepatitis B virus DNA positive(precore mutant) chronic hepatitis B显示文摘 | Tassopoulos NC Volpes R Pastore G | 1999 | Hepatology1999，，： | 1 |
| 20 | A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative显示文摘 | Sypsa VA Mimidis K Tassopoulos NC | 2005 | Hepatology2005，42，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员